[en] Chronic inflammation is recognized as a contributing factor to the development, progression and complications of atherosclerosis. The inflammatory nature of atherosclerosis has been proven by the presence of inflammatory cells, cytokines and chemokines at all stages of the disease. There is a widely accepted association between cardiovascular events and serum inflammatory markers, such as CRP, IL-6 and IL-1? produced via the inflammasome pathway. The involvement of inflammatory processes in atherosclerosis and progress in the therapeutic strategy are detailed in the article.
Disciplines :
Cardiovascular & respiratory systems
Author, co-author :
CAGNINA, Aurélien ; Centre Hospitalier Universitaire de Liège - CHU > > Service de cardiologie
Chabot, O; Service de Cardiologie, CHU Liège, Belgique.
Davin, Laurent ; Centre Hospitalier Universitaire de Liège - CHU > > Service de cardiologie
Lempereur, Mathieu ; Centre Hospitalier Universitaire de Liège - CHU > > Service de cardiologie
Marechal, Patrick ; Centre Hospitalier Universitaire de Liège - CHU > > Service de cardiologie
Hansson GK, Hermansson A. The immune system in atherosclerosis. Nature Immunol 2011;12:204-12.
Lusis AJ. Atherosclerosis. Nature 2000;407:233-41.
Ridker PM. From CANTOS to CIRT to COLCOT to Clinic: will all atherosclerosis patients soon be treated with combination lipid-lowering and inflammation-inhibiting agents? Circulation 2020;141:787-9.
Navarro-Cano G, del Rincón I, Pogosian S, et al. Association of mortality with disease severity in rheumatoid arthritis, independent of comorbidity. Arthritis Rheum 2003;48:2425-33.
Tazi Mezalek Z, Harmouche H, Ammouri W, et al. Athérosclérose au cours du lupus érythémateux systémique. Presse Med 2014;43:1034-47.
Horvath GL, Schrum JE, de Nardo CM, Latz E. Intracellular sensing of microbes and danger signals by the inflammasomes. Immunol Rev 2011;243:119-35.
Martinon F, Burns K, Tschopp J. The inflammasome: a molecular platform triggering activation of inflammatory caspases and processing of proIL-beta. Mol Cell 2002;10:417-26.
Kelley N, Jeltema D, Duan Y, He Y. The NLRP3 inflammasome: an overview of mechanisms of activation and regulation. Int J Mol Sci 2019;20:3328.
Rajamäki K, Lappalainen J, Öörni K, et al. Cholesterol crystals activate the NLRP3 inflammasome in human macrophages: a novel link between cholesterol metabolism and inflammation. PLoS One 2010;5:e11765.
Barbu E, Popescu MR, Popescu AC, Balanescu SM. Inflammation as a precursor of atherothrombosis, diabetes and early vascular aging. Int J Mol Sci 2022;23:963.
Duewell P, Kono H, Rayner K, et al. NLRP3 inflammasomes are required for atherogenesis and activated by cholesterol crystals. Nature 2010;464:1357-61.
Afrasyab A, Qu P, Zhao Y, et al. Correlation of NLRP3 with severity and prognosis of coronary atherosclerosis in acute coronary syndrome patients. Heart Vessels 2016;31:1218-29.
Ibáñez B, Heusch G, Ovize M, Van de Werf F. Evolving therapies for myocardial ischemia/reperfusion injury. J Am Coll Cardiol 2015;65:1454-71.
Libby P. Targeting inflammatory pathways in cardiovascular disease: the Inflammasome, interleukin-1, interleukin-6 and beyond. Cells 2021;10:951.
Campbell LA, Rosenfeld ME. Infection and atherosclerosis development. Arch Med Res 2015;46:339-50.
Pothineni NV, Subramany S, Kuriakose K, et al. Infections, atherosclerosis, and coronary heart disease. Available from: https://academic.oup.com/eurheartj/articleabstract/ 38/43/3195/3958174.
Aherrahrou R, Guo L, Nagraj VP, et al. Genetic regulation of atherosclerosis-relevant phenotypes in human vascular smooth muscle cells. Circ Res 2020;127:1552-65.
Rafieian-Kopaei M, Setorki M, Doudi M, et al. Atherosclerosis: process, indicators, risk factors and new hopes. Int J Prev Med 2014;5:927-46.
Lorenzatti AJ. Anti-inflammatory treatment and cardiovascular outcomes: results of clinical trials. Eur Cardiol 2021;16:e15.
Ridker PM. A Test in context: high-sensitivity C-reactive protein. J Am Coll Cardiol 2016;67:712-23.
Byrne RA, Colleran R. Aspirin for secondary prevention of cardiovascular disease. Lancet 2020;395:1462-3.
Steering Committee of the Physicians' Health Study Research Group. Final report on the aspirin component of the ongoing Physicians' Health Study. N Engl J Med 1989;321:129-35.
Zhang L, Li T, Miao X, et al. Aspirin suppresses NFκB1 expression and inactivates cAMP signaling pathway to treat atherosclerosis. Biofactors 2019;45:343-54.
Lu L, Liu H, Peng J, et al. Regulations of the key mediators in inflammation and atherosclerosis by spirin in human macrophages. LipidsHealth Dis 2010;9:16.
Chistiakov DA, Melnichenko AA, Grechko AV, et al. Potential of anti-inflammatory agents for treatment of atherosclerosis. Exp Mol Pathol 2018;104:114-24.
McNeil JJ, Wolfe R, Woods RL et al. Effect of Aspirin on cardiovascular events and bleeding in the healthy elderly. N Engl J Med 2018;379:1509-18.
Ridker PM, Danielson E, Fonseca FA, et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 2008;359:2195-207.
Jialal I, Stein D, Balis D, et al. Effect of hydroxymethyl glutaryl coenzyme a reductase inhibitor therapy on high sensitive C-reactive protein levels. Circulation 2001;103:1933-5.
Bohula EA, Giugliano RP, Leiter LA, et al. Inflammatory and cholesterol risk in the FOURIER trial. Circulation 2018;138:131-40.
Ridker PM, Everett BM, Pradhan A, et al. Low-dose methotrexate for the prevention of atherosclerotic events. N Engl J Med 2019;380:752-62.
Schönbeck U, Sukhova GK, Graber P, et al. Augmented expression of cyclooxygenase-2 in human atherosclerotic lesions. Am J Pathol 1999;155:1281-91.
Hong BK, Kwon HM, Lee BK, et al. Coexpression of cyclooxygenase- 2 and matrix metalloproteinases in human aortic atherosclerotic lesions. Yonsei Med J 2000;41:82-8.
Kearney PM, Baigent C, Godwin J, et al. Do selective cyclooxygenase- 2 inhibitors and traditional non-steroidal antiinflammatory drugs increase the risk of atherothrombosis? Meta-analysis of randomised trials. BMJ 2006;332:1302-8.
Jacob S, Laury-Kleintop L, Lanza-Jacoby S. The select cyclooxygenase-2 inhibitor celecoxib reduced the extent of atherosclerosis in apo E-/-mice. J Surg Res 2008;146:135-42.
Nissen SE, Yeomans ND, Solomon DH et al. Cardiovascular safety of celecoxib, naproxen, or ibuprofen for arthritis. N Engl J Med 2016;375:2519-29.
Bally M, Dendukuri N, Rich B et al. Risk of acute myocardial infarction with NSAIDs in real world use: bayesian meta-analysis of individual patient data. BMJ 2017;357: j1909.
Ridker PM, Everett BM, Thuren T, et al. Antiinflammatory therapy with canakinumab for atherosclerotic disease. N Engl J Med 2017;377:1119-31.
Nidorf SM, Fiolet AT, Mosterd A, et al. Colchicine in patients with chronic coronary disease. N Engl J Med 2020;383:1838-47.
Bouabdallaoui N, Tardif JC, Waters DD, et al. Time-to-treatment initiation of colchicine and cardiovascular outcomes after myocardial infarction in the Colchicine Cardiovascular Outcomes Trial (COLCOT). Eur Heart J 2020;41:4092-9.
Fiolet AT, Opstal TS, Mosterd A, et al. Efficacy and safety of low-dose colchicine in patients with coronary disease: a systematic review and meta-analysis of randomized trials. Eur Heart J 2021;42:2765-75.
Visseren FL, Mach F, Smulders YM, et al. 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J 2021;42:3227-337.
Abbate A, Wohlford GF, del Buono MG, et al. Interleukin-1 blockade with anakinra and heart failure following ST-segment elevation myocardial infarction: results from a pooled analysis of the VCUART clinical trials. Eur Heart J Cardiovasc Pharmacother 2021;pvab075.
Ridker PM, Devalaraja M, Baeres FM, et al. IL-6 inhibition with ziltivekimab in patients at high atherosclerotic risk (RESCUE): a double-blind, randomised, placebo-controlled, phase 2 trial. Lancet 2021;397:2060-9.
